From AI to Biotech: The Earnings Week Everyone’s Watching 👀

😎 Market Vibes

📅 Looking Ahead: Q2 Earnings for the Week of August 4, 2025
Next week's earnings slate is stacked - from AI darlings and chipmakers to biotech beasts and consumer giants. We're breaking down the most hyped Q2 reports set to drop, and what traders are watching as the numbers roll in.

But first…

Check this out from our partners at StockEarnings👇

Stop Guessing. Start Profiting This Earnings Season – Get the Free Guide

Let’s be real, earnings season can make or break your investment strategy. But what if you could always be one step ahead? 💡

Our Earnings Season eBook is exactly what you need to position yourself before the market shifts.
^{_{(**By clicking this link you agree to receive emails from StockEarnings and our affiliates. You can opt out at any time.  Privacy Policy. **)}}

The market’s moving, and you need to move with it. Don’t miss your chance to get ahead.

Download the eBook now!
^{_{(**By clicking this link you agree to receive emails from StockEarnings and our affiliates. You can opt out at any time.  Privacy Policy. **)}}

👀 All Eyes On Earnings

• 📊 Palantir's Big Monday Moment: PLTR drops Q2 earnings Monday after close - traders are praying AI government contracts actually print revenue this time.

• 💉 Biotech Double Tap Incoming: VRTX and AMGN report Monday and Tuesday - high expectations for drug pipelines, but whispers say guidance might underwhelm.

• 💾 SMCI's AI Reality Check: Super Micro reports Tuesday after the bell - stock's on a heater, but investors are bracing for either a moonshot or meltdown.

• 🧠 Quantum Hype Gets a Test: IonQ and D-Wave both report this week - forecast is big rev growth, but still deep in loss territory.

• 🎫 Uber & Lyft Hit the Road: Both ride-share giants report Wednesday - investors want proof that profits aren't just surge pricing and vibes. Lyft especially needs to show it's not permanently stuck in Uber's shadow.

💸 Trade Talk

Palantir reports Monday after the bell, and it’s either going to launch the AI rally into orbit or nuke it into the floor. The stock’s doubled this year, expectations are sky-high, and one bad line in guidance could unravel the whole narrative. Traders are loaded - now it’s showtime.

^_[sponsored]

The Next Big Gold Play: 1 Oz of Gold Exposure for $20

Gold is set to skyrocket, but most people don’t know about this under-$20 stock that offers a stake in more than an ounce of gold. Click here for urgent details before the market catches on.

🧠 Big Brain Energy

Quantum names IonQ and D-Wave report this week. Both are growing fast, but still losing money - traders want to see if the hype is turning into real results.

What are analysts expecting?

Wall Street expects IonQ to lose $0.30 per share in Q2 - worse than its $0.18 loss a year ago - but revenue should jump 52% to $17.3 million. Next quarter, sales could hit $25.6 million.

D‑Wave is expected to lose $0.05 per share, improving from a $0.10 loss last year. Revenue should grow 17% to $2.6 million, with Q3 estimates at $3.2 million.

🧨The Outrage Meter

Biotech stocks love to overpromise, and this week might be no different. Vertex and Amgen report this week with sky-high pipeline hopes… but if guidance stinks or trials stumble, expect a swift biotech beatdown.

Want to compare the two? Check this out.

🤔What Do You Think?

✌️ Thanks for vibing with us.

⚠️ WARNING: Market data is subject to rapid change. Verify current information before making trading decisions.

DISCLAIMER: Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in the linked report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in the linked report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted. For full disclaimer information, click here.